Search Details

Word: kohlberg (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...strengthen ties with industry and bring more inventions to the marketplace, Harvard has hired Isaac T. Kohlberg to reorganize its historically lethargic tech transfer office...

Author: By Nicholas M. Ciarelli and Daniel J. T. Schuker, CRIMSON STAFF WRITERSS | Title: Tear Down This Wall? | 5/23/2007 | See Source »

Turns out the barbarians at the gate--Henry Kravis of Kohlberg Kravis Roberts & Co. and David Bonderman of Texas Pacific Group (TPG)--have a little tree hugger in them. Even before the deal with TXU was sealed, the buyout shops called up environmentalists and, in a 17-hr. meeting at San Francisco's Mandarin Oriental Hotel, agreed to roll back carbon emissions from all TXU power plants to 1990 levels by 2020. Four days later, the company's board accepted the buyout offer, agreeing to drop controversial plans for eight of 11 new coal-fired power plants and to support...

Author: /time Magazine | Title: The Big Deal Goes Green | 3/2/2007 | See Source »

...Basically it’s a gift to a not-for-profit,” says Kohlberg, Harvard’s senior associate provost and chief technology development officer. “We all felt it was the right thing to do.” Both the University and Edwards say the move will fuel future research by MEND—and lower medicine costs for people in developing countries...

Author: By Nicholas M. Ciarelli and Daniel J. T. Schuker, CRIMSON STAFF WRITERSS | Title: A New Deal On Lifesaving Drugs | 11/13/2006 | See Source »

When the Gates Foundation agreed to fund Edwards’ project, it stipulated that Harvard would have to license the technology to MEND and that Harvard could not take royalties from MEND’s sales to the developing world, Kohlberg says...

Author: By Nicholas M. Ciarelli and Daniel J. T. Schuker, CRIMSON STAFF WRITERSS | Title: A New Deal On Lifesaving Drugs | 11/13/2006 | See Source »

...Kohlberg, Harvard’s licensing chief, says his office would prefer companies to allow access to developing countries when negotiating licenses. But according to Kohlberg, the University often finds itself stuck between two unappealing prospects—either ivory tower innovations will never reach consumers, or Harvard will be bound by strict licensing agreements that prevent developing-world customers from buying medicines cheaply...

Author: By Nicholas M. Ciarelli and Daniel J. T. Schuker, CRIMSON STAFF WRITERSS | Title: A New Deal On Lifesaving Drugs | 11/13/2006 | See Source »

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next